Replies to post #196582 on Biotech Values

[genisi]

Teva would have got epipen approved long time ago with MNTA's characterization techniques.

Think the difficulty in this case is with the auto-injector delivery device not epinephrine itself. So I don't think Teva would have done better partnering with Momenta than with Antares on generic EpiPen.